The Safety of Fecal Microbiota Transplantation for Crohn’s Disease: Findings from A Long-Term Study

Advances in Therapy

Volumn 35, Issue 11, 2018, Pages 1935-1944

  Wang, Honggang ^a,b   Cui, Bota ^a,c   Li, Qianqian ^a,c   Ding, Xiao ^a,c   Li, Pan ^a,c   Zhang, Ting ^a,c   Yang, Xiaozhong ^b   Ji, Guozhong ^a,c   Zhang, Faming ^a,c,d  

^a THE SECOND AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b THE AFFILIATED HUAIAN NO 1 PEOPLE S HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^c NANJING MEDICAL UNIVERSITY   (China)

^d National Clinical Research Center for Oral Diseases   (China)

Author keywords

Adverse event; Crohn s disease; Fecal microbiota transplantation; Gastroenterology; Safety

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; MESALAZINE; PREDNISONE; STEROID;

ABDOMINAL PAIN; ADULT; ARTICLE; BLOATING; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CROHN DISEASE; DEFECATION; DISEASE SEVERITY; FECAL MICROBIOTA TRANSPLANTATION; FECES MICROFLORA; FEMALE; FEVER; FLATULENCE; HERPES ZOSTER; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MIDGUT; PATIENT SAFETY; PROSPECTIVE STUDY; RECTUM HEMORRHAGE; RISK FACTOR; ADVERSE EVENT; CHINA; CLINICAL TRIAL; COHORT ANALYSIS; MIDDLE AGED; PHASE 4 CLINICAL TRIAL; PROCEDURES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TIME; TREATMENT OUTCOME;

ADULT; CHINA; COHORT STUDIES; CROHN DISEASE; FECAL MICROBIOTA TRANSPLANTATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT SAFETY; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TIME; TREATMENT OUTCOME;

EID: 85055438820     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-018-0800-3     Document Type: Article

References (26)

1. Wlodarska M, Kostic AD, Xavier RJ. An integrative view of microbiome-host interactions in inflammatory bowel diseases. Cell Host Microbe. 2015;17:577–91
2. Zhang FM, Wang HG, Wang M, et al. Fecal microbiota transplantation for severe enterocolonic fistulizing Crohn’s disease. World J Gastroenterol. 2013;19:7213–6
3. Suskind DL, Brittnacher MJ, Wahbeh G, et al. Fecal microbial transplant effect on clinical outcomes and fecal microbiome in active Crohn’s disease. Inflamm Bowel Dis. 2015;21:556–63
4. Gordon H, Harbord M. A patient with severe Crohn’s colitis responds to Faecal Microbiota Transplantation. J Crohns Colitis. 2014;8:256–7
5. Kao D, Hotte N, Gillevet P, et al. Fecal microbiota transplantation inducing remission in Crohn’s colitis and the associated changes in fecal microbial profile. J Clin Gastroenterol. 2014;48:625–8
6. Cui B, Feng Q, Wang H, et al. Fecal microbiota transplantation through mid-gut for refractory Crohn’s disease: safety, feasibility, and efficacy trial results. J Gastroenterol Hepatol. 2015;30:51–8
7. He Z, Li P, Zhu J, et al. Multiple fresh fecal microbiota transplants induces and maintains clinical remission in Crohn’s disease complicated with inflammatory mass. Sci Rep. 2017;7:4753
8. Van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368:407–15
9. Kelly C, Khoruts A, Staley C, et al. Effect of fecal microbiota transplantation on recurrence in multiply recurrent clostridium difficile infection: a randomized trial. Ann Intern Med. 2016;165:609–16
10. Jiang Z, Ajami NJ, Petrosino JF, et al. Randomised clinical trial: faecal microbiota transplantation for recurrent Clostridum difficile infection–fresh, or frozen, or lyophilised microbiota from a small pool of healthy donors delivered by colonoscopy. Aliment Pharmacol Ther. 2017;45:899–908
11. Ott SJ, Waetzig GH, Rehman A, et al. Efficacy of sterile fecal filtrate transfer for treating patients with Clostridium difficile infection. Gastroenterology. 2017;152:799–811
12. Paramsothy S, Kamm MA, Kaakoush NO, et al. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Lancet. 2017;389:1218–28
13. Moayyedi P, Surette MG, Kim PT, et al. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology. 2015;149:102–9
14. Rossen NG, Fuentes S, van der Spek MJ, et al. Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis. Gastroenterology. 2015;149:110–8
15. Uygun A, Ozturk K, Demirci H, et al. Fecal microbiota transplantation is a rescue treatment modality for refractory ulcerative colitis. Medicine. 2017;96:e6479
16. Angelberger S, Reinisch W, Makristathis A, et al. Temporal bacterial community dynamics vary among ulcerative colitis patients after fecal microbiota transplantation. Am J Gastroenterol. 2013;108:1620–30
17. Hoffmann D, Palumbo F, Ravel J, et al. Improving regulation of microbiota transplants. Science. 2017;358:1390–1
18. Kelly CR, Ihunnah C, Fischer M, et al. Fecal microbiota transplant for treatment of Clostridium difficile infection in immunocompromised patients. Am J Gastroenterol. 2014;109:1065–71
19. Vaughn BP, Vatanen T, Allegretti JR, et al. Increased intestinal microbial diversity following fecal microbiota transplant for active Crohn’s disease. Inflamm Bowel Dis. 2016;22:2182–90
20. Karolewska-Bochenek K, Grzesiowski P, Banaszkiewicz A, et al. A two-week fecal microbiota transplantation course in pediatric patients with inflammatory bowel disease. Adv Exp Med Biol. 2018;1047:81–7
21. Cui B, Li P, Xu L, et al. Step-up fecal microbiota transplantation (FMT) strategy. Gut Microbes. 2016;7:323–8
22. Bak SH, Choi HH, Lee J, et al. Fecal microbiota transplantation for refractory Crohn’s disease. Intest Res. 2017;15:244–8
23. Zhang T, Xiang J, Cui B, et al. Cost-effectiveness analysis of fecal microbiota transplantation for inflammatory bowel disease. Oncotarget. 2017;8:88894–903
24. Jeon SR, Chai J, Kim C, et al. Current evidence for the management of inflammatory bowel diseases using fecal microbiota transplantation. Curr Infect Dis Rep. 2018;20:21
25. Kelly CR, Kim AM, Laine L, et al. The AGA’s fecal microbiota transplantation national registry: an important step toward understanding risks and benefits of microbiota therapeutics. Gastroenterology. 2017;152:681–4
26. Zhang F, Cui B, He X, et al. Microbiota transplantation: concept, methodology and strategy for its modernization. Protein Cell. 2018;9:462–73